TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34061883
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment delivered in hospital outpatient clinics.
Study: 34590334
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ghrelin infusion (3 µg/kg loading dose followed by 16.9 ng/kg/min continuous infusion)
Study: 34883036
Drug: Sequential IPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IPC regimen
Study: 34883036
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (LymphAssist and Sequential IPC)
Study: 34863622
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block (CEB) with GA, 0.2% ropivacaine 1 ml/kg (n=25)
Study: 35777410
Drug: 6-month PrEP
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month PrEP dispensing plus interim oral fluid-based HIVST (with biannual clinic visits)
Study: 36164947
Drug: Omalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (300 mg/month, min-max=150-1200 mg)
Study: 36164947
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg/month for 2 patients with EGPA)
Study: 36164947
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment interruption
Study: 36164947
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of biological use
Study: 33822368
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (D‐Rd)
Study: 34230150
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel)
Study: 34230150
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel) followed by total mesometrial resection (TMMR) and adjuvant chemotherapy (ACT)
Study: 35604179
Drug: Self-made acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-made acne prescription taken orally
Study: 35604179
Drug: Chinese patent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese patent medicine Qingre Anchuang taken orally (Control)
Study: 34364382
Drug: Nomograms for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomograms for overall survival (OS) and cancer-specific survival (CSS) based on independent prognostic factors including age, sex, tumor size, grade, chemotherapy, N stage, and M stage.
Study: 35476124
Drug: Electronic tool
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic tool to detect and reduce complexity of drug treatment
Study: 33206382
Drug: 8U/kg abobotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8U/kg abobotulinumtoxinA injections
Study: 33206382
Drug: 16U/kg abobotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16U/kg abobotulinumtoxinA injections
Study: 35688588
Drug: Nurse-led peer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led peer support intervention (6 weekly peer support sessions facilitated by a nurse and at least one peer facilitator)
Study: 35688588
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly individual face-to-face sessions for 6 weeks)
Study: 33080005
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg up to 800 mg, intravenous within 8 hours from randomization, followed by a second dose after 12 hours)
Study: 35213716
Drug: Histamine-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 receptor blockers
Study: 32185993
Drug: Pricking and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking and penetrating moxibustion therapy
Study: 32185993
Drug: Penetrating moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penetrating moxibustion therapy (Control)
Study: 32078683
Drug: 0.40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 mg/kg tenecteplase (maximum, 40 mg; n = 150)
Study: 32078683
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg tenecteplase (maximum, 25 mg; n = 150)
Study: 32078683
Drug: 0.40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 mg/kg tenecteplase
Study: 32740347
Drug: Beta-blocker (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (BB)
Study: 35493500
Drug: Remdesivir, hyperimmune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir, hyperimmune plasma, and corticosteroids (treatment during flares)
Study: 32788067
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment for Bell's palsy
Study: 35218604
Drug: Trazpiroben 25
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 25 mg alone
Study: 35218604
Drug: Trazpiroben 25
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 25 mg with esomeprazole 40 mg
Study: 32223086
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg) plus tamsulosin hydrochloride (0.2 mg)
Study: 32223086
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg) only
Study: 32086898
Drug: Spirolactone 20
Normalized name: spironolactone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirolactone 20 mg orally twice a day for 7 days after H-UPPP
Study: 34282866
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment every 2 months for a total of 3 sessions
Study: 33590901
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc supplement
Study: 32315461
Drug: Drug Burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Burden Index (DBI) assessment
Study: 32092717
Drug: Bisoprolol patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol patch
Study: 33010934
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg of palonosetron (Group 1)
Study: 33010934
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of ondansetron associated with 4 mg of dexamethasone (Group 2)
Study: 33010934
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of dexamethasone (Group 3)
Study: 36443585
Drug: Phloroglucinol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol (oral or IV/IM)
Study: 36443585
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (dexketoprofen for urinary spasms and pain; metamizole or scopolamine for biliary colic)
Study: 36484189
Drug: Celecoxib capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib capsules, 0.2 g twice a day (medication group)
Study: 33009349
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (350 mg·d ‐1 , 10 days)
Study: 33771903
Drug: high-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose octreotide LAR
Study: 32323462
Drug: Peeling with
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peeling with 70% glycolic acid followed by 5% 5-fluorouracil cream
Study: 32323462
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream (twice daily)
Study: 35686572
Drug: V-01 vaccine
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-01 vaccine
Study: 34247582
Drug: Physical exercises
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercises with elements of dance movement therapy (DMT), 30-min session, two times a week for 12 weeks
Study: 33605029
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 or 200 mg/day for 5 days)
Study: 33605029
Drug: Triamcinolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (40 mg in a single injection)
Study: 34776136
Drug: Foam pad
Normalized name: BARRIER,FOAM PAD TORBOT #431R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam pad balance exercises (60 min/day, twice/week for 6 weeks)
Study: 33974170
Drug: tDCS combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS combined with conventional comprehensive treatment
Study: 33974170
Drug: Conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional comprehensive treatment
Study: 36006613
Drug: Therapeutic-dose bodyweight-adjusted
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose bodyweight-adjusted oral rivaroxaban (n=40)
Study: 36006613
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation with heparins, with or without vitamin K antagonists (n=16)
Study: 32034016
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg orvepitant
Study: 32034016
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg orvepitant
Study: 36108603
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia prior to mydriatic drops
Study: 34606529
Drug: Exogenous ketone
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous ketone supplement (β‐hydroxybutyrate)
Study: 35686380
Drug: Celecoxib-tramadol co-crystal
Normalized name: celecoxib / tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib-tramadol co-crystal (CTC) 200 mg every 12 h
Study: 35686380
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg every 6 h
Study: 35686380
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg every 12 h
Study: 33605620
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin at a dose of 40 mg/kg/day for 3-5 days
Study: 33605620
Drug: Nebulized colistimethate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized colistimethate sodium (CMS) at a dose of 15 million IU/day for 3-5 days
Study: 33605620
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of a new cephalosporine/ß-lactamase inhibitor for 7 days
Study: 33605620
Drug: Nebulized CMS
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized CMS at a dose of 15 million IU/day for VAP caused by pandrug-resistant GNB
Study: 33605620
Drug: Intravenous CMS
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CMS at a dose of 9 million IU/day
Study: 32741773
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day ubiquinol from 7 days before to 5 days after surgery
Study: 36086930
Drug: Dexamethasone OMP
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone OMP (5 mg/week)
Study: 34888277
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH) delivered by CDDs.
Study: 34520520
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (5 mcg/kg)
Study: 34666202
Drug: Yogurt (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt (220 g/d)
Study: 34666202
Drug: Milk (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (220 g/d)
Study: 32129141
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of GO-ON (5 mL)
Study: 32129141
Drug: Three repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three repeated doses of GO-ON (2.5 mL each)
Study: 32129141
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of single-dose injection
Study: 33201535
Drug: 0.1, 0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1, 0.2, or 0.3 mg/kg bumetanide
Study: 35272940
Drug: Vasopressin injection
Normalized name: Vasopressin Injection
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin injection during ovarian cystectomy
Study: 35272940
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vasopressin injection)
Study: 36227421
Drug: Ropivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine group (group N, 0.375% ropivacaine 40 ml + normal saline 4 ml)
Study: 36227421
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate group (group M, 0.375% ropivacaine 40 ml + 10% magnesium sulfate 4 ml)
Study: 36227421
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C, normal saline 44 ml)
Study: 33472301
Drug: Betahistine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (12 mg orally three times a day for four weeks)
Study: 32499125
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 (20 g/d for IBS-C) / Pinaverium bromide (150 mg/d for IBS-D)
Study: 34116873
Drug: 3-antigen hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-antigen hepatitis B vaccine (3A-HBV) lot A
Study: 34116873
Drug: 3-antigen hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-antigen hepatitis B vaccine (3A-HBV) lot B
Study: 34116873
Drug: 1-antigen hepatitis
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-antigen hepatitis B vaccine (1A-HBV) Engerix-B
Study: 32193758
Drug: Model performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model performance with external data from drug banks and ZINC database
Study: 32193758
Drug: Misclassified non-drug
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misclassified non-drug small molecules
Study: 33482247
Drug: Imatinib, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib, 400 mg daily for 2 years
Study: 33482247
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy after surgery
Study: 33727409
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment, aimed at average systolic BP reduction by 10%-20% within the first 24 hours and achieving BP <140/90 mm Hg within 5 days.
Study: 33727409
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment, no antihypertensive medications for the first 7 days, then achieving BP <140/90 mm Hg after 7 days.
Study: 34523673
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily for 21 days
Study: 32851636
Drug: Caffeine (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6.5 mg·kg‐1 body mass)
Study: 32851636
Drug: Carbohydrate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (6 g of maltodextrin rinsed for 10 s)
Study: 36173609
Drug: Doxycycline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (50 mg once daily for 12 weeks)
Study: 36158665
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel 135 mg/m2 plus mFOLFOX6
Study: 36158665
Drug: Intraperitoneal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel 80 mg/m2 plus mFOLFOX6
Study: 35280907
Drug: Sarilumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (single 400 mg dose in two 200 mg subcutaneous injections)
Study: 33164259
Drug: Clonidine or
Normalized name: clonidine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine or spironolactone (fourth drug)
Study: 33164259
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antihypertensive drugs (first phase V0-V3)
Study: 36400418
Drug: ANT14 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT14 (14 days of antofloxacin-based bismuth quadruple therapy)
Study: 36400418
Drug: ANT10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT10 (10 days of antofloxacin-based bismuth quadruple therapy)
Study: 36400418
Drug: CLA14 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA14 (14 days of clarithromycin-based bismuth quadruple therapy)
Study: 33599841
Drug: De-escalation treatment
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation treatment options (cetuximab-based radiotherapy)
Study: 33599841
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) protocols
Study: 33755110
Drug: PN-HPT (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-HPT (4.0 mL)
Study: 33755110
Drug: Placebo (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4.0 mL normal saline)
Study: 35232423
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral Dydrogesterone daily
Study: 35232423
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intramuscular 17α‐OHPC weekly
Study: 33818170
Drug: Tafluprost (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafluprost (15 mg/ml)
Study: 33818170
Drug: Bimatoprost (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost (0.1 mg/ml)
Study: 32122898
Drug: Intravenous dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dalbavancin at 1,500 mg
Study: 32122898
Drug: Intraperitoneal dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal dalbavancin at 1,500 mg
Study: 35748757
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (external concurrent occipital and trigeminal neurostimulation)
Study: 34151818
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapies (non-PMRT group)
Study: 32106141
Drug: efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz (600 mg daily with NRTIs)
Study: 32106141
Drug: atazanavir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atazanavir/ritonavir (300/100 mg daily with NRTIs)
Study: 33657959
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nano-curcumin
Study: 32328824
Drug: Endoscopist experience
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopist experience with <20 G‐POEM procedures
Study: 32328824
Drug: Endoscopist experience
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopist experience with >20 G‐POEM procedures
Study: 35854236
Drug: Toripalimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg) every 3 weeks during concurrent chemoradiotherapy and once every 6 weeks after consolidation chemotherapy for up to 1 year.
Study: 35854236
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with intensity modulated radiotherapy and high‐dose rate brachytherapy, along with weekly DDP (40 mg/m2) during radiotherapy and 6 cycles of consolidated chemotherapy (paclitaxel plus DDP) after radiotherapy.
Study: 35666852
Drug: Budesonide oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide oral suspension (BOS) low dose: 0.35 or 0.5 mg; high dose: 1.4 or 2.0 mg
Study: 34027030
Drug: Atomoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks)
Study: 35045980
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 mL oral dose)
Study: 34370975
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of renin-angiotensin system inhibitors
Study: 34370975
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of renin-angiotensin system inhibitors
Study: 32402681
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with bevacizumab (6 cycles of FOLFOX/FOLFIRI before and after surgery)
Study: 32402681
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with bevacizumab (12 cycles after surgery)
Study: 32402681
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with bevacizumab (in subgroup with CEA ≥ 5 ng/mL)
Study: 32402681
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with bevacizumab (in subgroup with over 2 liver metastases)